The use of systemic immune moderators in dermatology: An update

被引：35

作者：

Stern, DK

Tripp, JM

Ho, VC

Lebwohl, M

机构：

[1] Mt Sinai Med Ctr, Mt Sinai Sch Med, Clin Trials Ctr, Dept Dermatol, New York, NY 10029 USA

[2] Vancouver Hosp & Hlth Sci Ctr, Dept Med, Div Dermatol, Vancouver, BC V5Z 4E8, Canada

[3] Univ British Columbia, Vancouver, BC V5Z 4E8, Canada

来源：

DERMATOLOGIC CLINICS | 2005年 / 23卷 / 02期

关键词：

D O I：

10.1016/j.det.2004.09.006

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

In addition to corticosteroids, dermatologists have access to an array of immunomodulatory therapies. Azathioprine, cyclophosphamide, methotrexate, cyclosporine, and mycophenolate mofetil are the systemic immunosuppressive agents most commonly used by dermatologists. In addition, new developments in biotechnology have spurred the development of immunobiologic agents that are able to target the immunologic process of many inflammatory disorders at specific points along the inflammatory cascade. Alefacept, efalizumab, etanercept, and infliximab are the immunobiologic agents that are currently the most well known and most commonly used by dermatologists. This article reviews the pharmacology, mechanism of action, side effects, and clinical applications of these therapies.

引用

页码：259 / +

页数：44

共 359 条

[1] A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis [J].